Naltrexone
- Generic Name
- Naltrexone
- Brand Names
- Contrave, Embeda, Vivitrol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23NO4
- CAS Number
- 16590-41-3
- Unique Ingredient Identifier
- 5S6W795CQM
- Background
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
- Indication
Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
- Associated Conditions
- Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
- Associated Therapies
- -
Neurobiology of Opioid Dependence: 4 - 4
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000195
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Neurobiology of Opioid Dependence: 5 - 5
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Yale University
- Registration Number
- NCT00000196
- Locations
- 🇺🇸
VA Connecticut Healthcare System, New Haven, Connecticut, United States
Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000307
- Locations
- 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.